Docetaxel in the treatment of metastatic hormone sensitive and castration-resistant prostate cancer: A meta-analysis.

被引：1
|
作者：
Zhang, Shijia
Sanchez, Larysa Jessica
Liu, Jieqi
Wang, Yucai
Duma, Narjust
Chang, Victor Tsu-Shih
Alter, Robert S.
Gutierrez, Martin
Sartor, A. Oliver
机构：
[1] Rutgers New Jersey Med Sch, Dept Med, Newark, NJ USA
[2] Rutgers New Jersey Med Sch, Newark, NJ USA
[3] VA New Jersey Hlth Care Syst, Hematol Oncol Sect, E Orange, NJ USA
[4] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[5] Tulane Univ, Sch Med, Dept Med & Urol, 1430 Tulane Ave, New Orleans, LA 70112 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e16505
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16505
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Schweizer, Michael T.
    Gulati, Roman
    Mostaghel, Elahe A.
    Nelson, Peter S.
    Montgomery, R. Bruce
    Yu, Evan Y.
    Cheng, Heather H.
    MEDICAL ONCOLOGY, 2016, 33 (07)
  • [2] Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Michael T. Schweizer
    Roman Gulati
    Elahe A. Mostaghel
    Peter S. Nelson
    R. Bruce Montgomery
    Evan Y. Yu
    Heather H. Cheng
    Medical Oncology, 2016, 33
  • [3] Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
    Marit A. C. Vermunt
    Merel van Nuland
    Lisa T. van der Heijden
    Hilde Rosing
    Jos. H. Beijnen
    Andries M. Bergman
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 785 - 793
  • [4] Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
    Vermunt, Marit A. C.
    van Nuland, Merel
    van der Heijden, Lisa T.
    Rosing, Hilde
    Beijnen, Jos H.
    Bergman, Andries M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (06) : 785 - 793
  • [5] Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer
    Mager, Rene
    Savko, Olga
    Boehm, Katharina
    Thomas, Anita
    Dotzauer, Robert
    Borgmann, Hendrik
    Jaeger, Wolfgang
    Thomas, Christian
    Haferkamp, Axel
    Hoefner, Thomas
    Tsaur, Igor
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (12) : 999 - 1005
  • [6] Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel
    Bilgetekin, Irem
    Basal, Fatma Bugdayci
    Cinkir, Havva Yesil
    Esin, Ece
    Oksuzoglu, Berna
    Demirci, Umut
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2020, 30 (08): : 815 - 821
  • [7] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Management of metastatic castration-resistant prostate cancer following docetaxel
    Beuzeboc, Philippe
    Ropert, Stanislas
    Goldwasser, Francois
    Zerbib, Marc
    BULLETIN DU CANCER, 2012, 99 : S66 - S72
  • [9] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [10] Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer
    Shen, Yuan-Chi
    Chiang, Po-Hui
    Luo, Hao-Lun
    Chuang, Yao-Chi
    Chen, Yen-Ta
    Kang, Chih-Hsiung
    Hsu, Chun-Chien
    Lee, Wei-Ching
    Cheng, Yuan-Tso
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2016, 32 (09): : 458 - 463
12345